Galmed Pharmaceuticals Ltd.
Qualité des données : 83%
GLMD
Nasdaq
Manufacturing
Chemicals
0,79 €
▲
0,16 €
(26,14%)
Cap. Boursière: 5,18 M
Prix
0,79 €
Cap. Boursière
5,18 M
Fourchette du Jour
0,76 € — 1,26 €
Fourchette 52 Semaines
0,41 € — 2,68 €
Volume
175 915 924
Ouverture 1,16 €
Moyenne 50J / 200J
0,62 €
25,79% above
Moyenne 50J / 200J
1,17 €
33,09% below
Quick Summary
Points Clés
Negative free cash flow of -6,32 M
Croissance
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-52,02%
Au-dessus de la moyenne du secteur (-53,41%)
ROICN/A
Net MarginN/A
Op. MarginN/A
Sécurité
Debt / Equity
N/A
Current Ratio7,98
Interest CoverageN/A
Valorisation
PE (TTM)
-0,50
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio0,27
EV/EBITDAN/A
Dividend YieldN/A
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1364 pairs)
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1364 pairs)| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -0,5 | -1,5 |
| P/B | 0,3 | 1,6 |
| ROE % | -52,0 | -53,4 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -10,31 M |
| ROE | -52,02% | ROA | -46,30% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -6,32 M |
| ROIC | N/A | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 7,98 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 17,25 M | Tangible Book Value | 19,11 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,50 | Forward P/E | N/A |
| P/B Ratio | 0,27 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -121,86% | ||
| Market Cap | 5,18 M | Enterprise Value | 1,87 M |
| Per Share | |||
| EPS (Diluted TTM) | 2,39 | Revenue / Share | N/A |
| FCF / Share | -0,96 | OCF / Share | -0,96 |
| EPS CAGR (1Y) | -70,42% | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 61,26% |
| SBC-Adj. FCF | -7,38 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -10,31 M | -7,52 M | -6,91 M | -17,87 M | -32,47 M |
| EPS (Diluted) | 2,39 | 8,08 | 2,50 | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 4,87 M | 2,98 M | 3,57 M | 13,00 M | 27,22 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 83 000,0 | 83 000,0 | 31 000,0 | 35 000,0 | 42 000,0 |
| Interest Expense | — | — | — | — | — |
| Income Tax | 0,0 | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 18,63 M | 18,50 M | 16,63 M | 16,56 M | 36,61 M |
| Total Liabilities | — | — | — | — | — |
| Shareholders' Equity | 15,78 M | 16,33 M | 13,88 M | 13,42 M | 30,50 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 3,99 M | 4,65 M | 2,86 M | 2,02 M | 2,88 M |
| Current Assets | 18,63 M | 16,12 M | 13,24 M | 14,72 M | 36,05 M |
| Current Liabilities | 2,85 M | 2,17 M | 2,75 M | 3,09 M | 5,88 M |
{"event":"ticker_viewed","properties":{"ticker":"GLMD","listing_kind":"stock","pathname":"/stocks/glmd","exchange":"Nasdaq","country":"US"}}